Karyopharm Therapeutics Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Karyopharm Therapeutics Inc. (KPTI) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $2.48 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $2.48M, a 352.46% increase year-over-year.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$2.90M, a 143.94% decline year-over-year.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $20.59M.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$1.13M, a 106.99% decline year-over-year.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $17.11M, a 30.44% decline from fiscal 2016.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $24.59M.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$90.82M.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$67.03M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 57 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 60 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 63 month |
|---|---|---|---|---|---|---|---|
| 2018-03-31 | $2.48M 10-Q · filed 2018-05-10 | -$417.00K derived: sum of 2 quarters · filed 2018-05-10 | $20.18M derived: sum of 3 quarters · filed 2018-05-10 | $19.04M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $17.69M derived: sum of 2 quarters · filed 2018-03-15 | $16.56M derived: sum of 3 quarters · filed 2018-03-15 | $17.11M 10-K · filed 2018-03-15 | |||
| 2017-09-30 | $20.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $19.46M derived: sum of 2 quarters · filed 2017-11-02 | $20.01M 10-Q · filed 2017-11-02 | $26.61M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-06-30 | -$1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$585.00K 10-Q · filed 2017-08-08 | $6.02M derived: sum of 3 quarters · filed 2018-05-10 | $1.04M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-03-31 | $549.00K 10-Q · filed 2018-05-10 | $7.15M derived: sum of 2 quarters · filed 2018-05-10 | $2.18M derived: sum of 3 quarters · filed 2018-05-10 | $18.39M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | $6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $1.63M derived: sum of 2 quarters · filed 2018-03-15 | $17.84M derived: sum of 3 quarters · filed 2018-03-15 | $24.59M 10-K · filed 2018-03-15 | |||
| 2016-09-30 | -$4.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $11.24M derived: sum of 2 quarters · filed 2017-11-02 | $17.99M 10-Q · filed 2017-11-02 | $51.84M derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2016-06-30 | $16.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $22.97M 10-Q · filed 2017-08-08 | $56.81M derived: sum of 3 quarters · filed 2018-03-15 | $101.37M derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2016-03-31 | $6.75M 10-Q · filed 2017-05-04 | $40.59M derived: sum of 2 quarters · filed 2018-03-15 | $85.15M derived: sum of 3 quarters · filed 2018-03-15 | $86.01M derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2015-12-31 | $33.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $78.40M derived: sum of 2 quarters · filed 2018-03-15 | $79.26M derived: sum of 3 quarters · filed 2018-03-15 | -$90.82M 10-K · filed 2018-03-15 | |||
| 2015-09-30 | $44.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $45.41M derived: sum of 2 quarters · filed 2016-11-07 | -$124.67M 10-Q · filed 2016-11-07 | -$188.56M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $858.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$169.22M 10-Q · filed 2016-08-04 | -$233.12M derived: sum of 3 quarters · filed 2017-03-16 | -$235.40M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | -$170.08M 10-Q · filed 2016-05-09 | -$233.98M derived: sum of 2 quarters · filed 2017-03-16 | -$236.26M derived: sum of 3 quarters · filed 2017-03-16 | -$236.59M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | -$63.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$66.18M derived: sum of 2 quarters · filed 2017-03-16 | -$66.51M derived: sum of 3 quarters · filed 2017-03-16 | -$67.03M 10-K · filed 2017-03-16 | |||
| 2014-09-30 | -$2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$2.61M derived: sum of 2 quarters · filed 2015-11-09 | -$3.13M 10-Q · filed 2015-11-09 | -$3.17M derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-06-30 | -$324.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$849.00K 10-Q · filed 2015-08-10 | -$881.00K derived: sum of 3 quarters · filed 2016-03-15 | ||||
| 2014-03-31 | -$525.00K 10-Q · filed 2015-05-11 | -$557.00K derived: sum of 2 quarters · filed 2016-03-15 | -$1.11M 10-Q · filed 2014-05-08 | ||||
| 2013-12-31 | -$32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$57.00K 10-K · filed 2016-03-15 | -$590.00K 10-K · filed 2014-03-21 | ||||
| 2013-09-30 | -$25.00K 10-Q · filed 2014-11-10 | -$558.00K 10-Q/A · filed 2013-12-23 | |||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2015-03-13 | -$121.00K 10-K · filed 2015-03-13 | |||||
| 2012-09-30 | -$121.00K 10-Q/A · filed 2013-12-23 | ||||||
| 2011-12-31 | -$376.00K 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |